Recent advances in the application of TAT, TM, t-PAIC and PIC in thromboembolism.
10.3760/cma.j.cn112150-20230507-00353
- Author:
Yong Jian LI
1
;
Qi ZHANG
2
;
Hong Chun WANG
3
Author Information
1. Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China.
2. School of Public Health, Shandong University, Jinan 250012, China.
3. Department of Clinical Laboratory, Qilu Hospital of Shandong University, Shandong Engineering Research Center of Biomarker and Artificial Intelligence Application, Jinan 250012, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Tissue Plasminogen Activator;
Plasminogen Inactivators;
Thrombomodulin;
Thromboembolism;
Biomarkers
- From:
Chinese Journal of Preventive Medicine
2023;57(10):1693-1703
- CountryChina
- Language:Chinese
-
Abstract:
Thromboembolism is a crucial part of the global disease burden. It has high incidence, high mortality and disability rates, and the mechanism of occurrence and development is extremely complex. It is difficult to detect the disease in the early stage so that we have trouble with clinical prevention and treatment in general. At present, four items of blood coagulation and D-dimer have been widely used in the evaluation and auxiliary diagnosis of thromboembolism, the monitoring of effect for antithrombotic drugs and other fields. The thrombus biomarkers including thrombin-antithrombin complex (TAT), thrombomodulin (TM), tissue plasminogen activator-inhibitor complex (t-PAIC) and α2-plasmin inhibitor-plasmin complex (PIC) fill the gap of laboratory diagnosis before clinical symptoms appear in some degree. This article aims to explain the current application status of TAT, TM, t-PAIC and PIC in thromboembolism and explore their potential application value, so as to provide a reference for selecting appropriate early monitoring indicators for high-risk population of thromboembolism.
